Edition:
India

Alimera Sciences Inc (ALIM.OQ)

ALIM.OQ on NASDAQ Stock Exchange Global Market

1.28USD
12 Jan 2018
Change (% chg)

-- (--)
Prev Close
$1.28
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
26,508
52-wk High
$1.71
52-wk Low
$1.11

Latest Key Developments (Source: Significant Developments)

Alimera Sciences Enters Into $40 Mln Term Loan Agreement With Solar Capital
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Alimera Sciences Inc ::ALIMERA SCIENCES INC- ENTERED INTO A $40 MILLION TERM LOAN AGREEMENT WITH SOLAR CAPITAL LTD.ALIMERA SCIENCES INC- TO USE PROCEEDS OF FUNDING TO PAY OFF AN EXISTING $35 MILLION TERM LOAN, TO PROVIDE ADDITIONAL WORKING CAPITAL.ALIMERA SCIENCES INC- TERM LOAN MATURES ON JULY 1, 2022.  Full Article

Alimera Sciences Inc reports qtrly loss per share ‍$0.08​
Thursday, 2 Nov 2017 

Nov 1 (Reuters) - Alimera Sciences Inc :Alimera Sciences Inc reports third quarter 2017 financial results.Q3 revenue rose 18 percent to $9.8 million.Alimera Sciences Inc qtrly loss per share ‍$0.08​.  Full Article

Great point reports 5.12 pct passive stake in Alimera Sciences - SEC filing
Tuesday, 23 Aug 2016 

Alimera Sciences Inc :Great Point Partners Llc reports 5.12 percent passive stake in alimera sciences inc as of Aug. 11 - sec filing.  Full Article

Alimera Sciences prices public offering of common stock
Thursday, 11 Aug 2016 

Alimera Sciences Inc : Alimera Sciences prices public offering of common stock .Says public offering of 18.0 million common shares priced at $1.40per share.  Full Article

Alimera Sciences proposes public offering of common stock
Thursday, 11 Aug 2016 

Alimera Sciences Inc : Alimera Sciences proposes public offering of common stock .All shares in offering are to be sold by Alimera, with net proceeds to be used to fund continued commercialization of Iluvien.  Full Article

Alimera Sciences Q2 GAAP loss per share $0.15
Thursday, 4 Aug 2016 

Alimera Sciences Inc : Alimera sciences announces second quarter 2016 financial results and provides business update . Q2 gaap loss per share $0.15 . Q2 adjusted non-gaap loss per share $0.17 . Q2 revenue rose 66 percent to $9.6 million . Alimera sciences inc says has engaged in discussions with fda regarding potential future indications for iluvien .Based on discussions, believes it should be able to establish adequate evidence of safety and efficacy for approval of iluvien for additional indication.  Full Article

Alimera Sciences sees Q2 revenue of $9.3 mln - $9.5 mln
Tuesday, 26 Jul 2016 

Alimera Sciences Inc: Announces record second quarter 2016 revenue . Sees Q2 2016 revenue $9.3 million to $9.5 million . Says modified liquidity and revenue covenants in its existing loan agreement with Hercules Capital Inc . Says modification allows for reduction of Alimera's liquidity threshold . Q2 revenue view $7.2 million -- Thomson Reuters I/B/E/S . Says modifies its liquidity and revenue covenants under its loan facility . Says Q2 2016 u.s. Revenue is expected to be in range of $7.0 million to $7.2 million .Says modification reduces Co's trailing three-month revenue requirement through period ending August 31, 2016.  Full Article

BRIEF-Alimera Sciences Enters Into $40 Mln Term Loan Agreement With Solar Capital

* ALIMERA SCIENCES INC- ENTERED INTO A $40 MILLION TERM LOAN AGREEMENT WITH SOLAR CAPITAL LTD